Publications by authors named "D Gazis"
Introduction: The benefit of adding an immunomodulator to vedolizumab and ustekinumab remains unclear and may compromise the safety of these biologics. We evaluated the prevalence and predictors of immunomodulator use with vedolizumab or ustekinumab in patients with inflammatory bowel disease in a large longitudinal cohort.
Methods: Clinical information was ascertained from electronic medical records of patients enrolled in TARGET-IBD, a prospective longitudinal observational cohort of patients with inflammatory bowel disease (IBD) at 34 sites.
Article Synopsis
- IBD treatment guidelines suggest using objective disease activity assessments and therapeutic drug monitoring (TDM) before altering biologic therapies in patients.
- In a study of over 2100 IBD patients, most who changed dosage or stopped biologics due to ineffectiveness had objective assessments, with CRP being the most common marker used.
- Objective assessments and TDM were performed in a significant number of patients prior to therapy changes, with variations noted between Crohn's disease and ulcerative colitis patients in terms of the tests used and frequency.
Goal: The goal of this study was to describe medication utilization patterns in older inflammatory bowel disease (IBD) patients.
Background: Despite a growing population of older patients with Crohn's disease (CD) and ulcerative colitis (UC), questions remain regarding medication utilization patterns in comparison to younger populations.
Materials And Methods: We collected data from the 34 sites in TARGET-IBD, a multicenter, observational cohort.
Background: Data on care patterns for inflammatory bowel disease (IBD) from large-scale, diverse clinical cohorts in real-world practice are sparse. We developed a real-world cohort of patients receiving care at academic and community sites, for comparative study of therapies and natural history of IBD.
Methods: We describe novel methodology of central abstraction of clinical data into a real-world IBD registry with patient reported outcomes (PROs).
Patients with nonalcoholic fatty liver disease (NAFLD) are at an increased risk of cardiovascular disease. Hydoxy-3-methyglutaryl-coenzyme reductase inhibitors, statins, reduce the risk of cardiovascular events. Studies have shown that statins are safe among patients with liver disease, including those with compensated cirrhosis, and their use is associated with lower mortality, hepatic decompensation, and possibly hepatocellular carcinoma.
View Article and Find Full Text PDF